EA201790817A1 - 2-амино-3,5-дифтор-3,6-диметил-6-фенил-3,4,5,6-тетрагидропиридины как ингибиторы bace1 для лечения болезни альцгеймера - Google Patents
2-амино-3,5-дифтор-3,6-диметил-6-фенил-3,4,5,6-тетрагидропиридины как ингибиторы bace1 для лечения болезни альцгеймераInfo
- Publication number
- EA201790817A1 EA201790817A1 EA201790817A EA201790817A EA201790817A1 EA 201790817 A1 EA201790817 A1 EA 201790817A1 EA 201790817 A EA201790817 A EA 201790817A EA 201790817 A EA201790817 A EA 201790817A EA 201790817 A1 EA201790817 A1 EA 201790817A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- disease
- diftor
- allzheimer
- tetrahydropyridines
- dimethyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Abstract
Настоящее изобретение относится к соединениям формулы Iпри этом соединения являются ингибиторами фермента ВАСЕ1. Отдельные аспекты настоящего изобретения относятся к фармацевтическим композициям, содержащим указанные соединения, и к применениям соединений для лечения нарушений, при которых полезно снижение отложений Аβ, таких как болезнь Альцгеймера.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA201400649 | 2014-11-10 | ||
DKPA201500450 | 2015-08-07 | ||
PCT/EP2015/076014 WO2016075062A1 (en) | 2014-11-10 | 2015-11-09 | 2-amino-3,5-difluoro-3,6-dimethyl-6-phenyl-3,4,5,6-tetrahydropyridines as bace1 inhibitors for treating alzheimer's disease |
Publications (1)
Publication Number | Publication Date |
---|---|
EA201790817A1 true EA201790817A1 (ru) | 2017-09-29 |
Family
ID=54476983
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201790817A EA201790817A1 (ru) | 2014-11-10 | 2015-11-09 | 2-амино-3,5-дифтор-3,6-диметил-6-фенил-3,4,5,6-тетрагидропиридины как ингибиторы bace1 для лечения болезни альцгеймера |
Country Status (26)
Country | Link |
---|---|
US (1) | US10059669B2 (ru) |
EP (1) | EP3218362B1 (ru) |
JP (1) | JP2017533253A (ru) |
KR (1) | KR20170082529A (ru) |
CN (1) | CN107074809A (ru) |
AU (1) | AU2015345257A1 (ru) |
BR (1) | BR112017009647A2 (ru) |
CA (1) | CA2964305A1 (ru) |
CL (1) | CL2017001113A1 (ru) |
CO (1) | CO2017004530A2 (ru) |
CR (1) | CR20170187A (ru) |
DO (1) | DOP2017000118A (ru) |
EA (1) | EA201790817A1 (ru) |
EC (1) | ECSP17028463A (ru) |
ES (1) | ES2710602T3 (ru) |
IL (1) | IL252091A0 (ru) |
MX (1) | MX2017006048A (ru) |
NI (1) | NI201700056A (ru) |
PE (1) | PE20170947A1 (ru) |
PH (1) | PH12017500829A1 (ru) |
RU (1) | RU2017116197A (ru) |
SG (1) | SG11201703177WA (ru) |
SV (1) | SV2017005434A (ru) |
TN (1) | TN2017000134A1 (ru) |
WO (1) | WO2016075062A1 (ru) |
ZA (1) | ZA201702799B (ru) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CR20170187A (es) | 2014-11-10 | 2018-02-01 | H Lundbeck As | 2-Amino-3,5-difluoro-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas en calidad de inhibidores de BACE1 para el tratamiento de la enfermedad de Alzheimer |
JO3458B1 (ar) | 2014-11-10 | 2020-07-05 | H Lundbeck As | 2- أمينو-6- (دايفلوروميثيل) – 5، 5- ديفلورو-6-فينيل-3،4، 5، 6-تيتراهيدروبيريدين كمثبطات bace1 |
MA40941A (fr) | 2014-11-10 | 2017-09-19 | H Lundbeck As | 2-amino-5,5-difluoro-6-(fluorométhyl)-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1 |
JO3627B1 (ar) | 2015-04-30 | 2020-08-27 | H Lundbeck As | إيميدازو بيرازينونات على هيئة مثبطات pde1 |
TW201717948A (zh) | 2015-08-10 | 2017-06-01 | H 朗德貝克公司 | 包括給予2-胺基-3,5,5-三氟-3,4,5,6-四氫吡啶的聯合治療 |
MX2018001699A (es) * | 2015-08-12 | 2018-05-07 | H Lundbeck As | 2-amino-3-fluoro-3-(fluorometil)-6-meti-6-fenil-3,4,5,6-tetrahidr opiridinas como inhibidores de bace1. |
US10034861B2 (en) | 2016-07-04 | 2018-07-31 | H. Lundbeck A/S | 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors |
CN106366073B (zh) * | 2016-10-24 | 2018-11-30 | 扬子江药业集团南京海陵药业有限公司 | 一种盐酸替吡嘧啶的制备方法 |
DK3532064T3 (da) | 2016-10-28 | 2020-08-24 | H Lundbeck As | Kombinationsbehandlinger omfattende imidazopyrazinoner til behandlingen af psykiatriske og/eller kognitive lidelser |
CN109803653A (zh) | 2016-10-28 | 2019-05-24 | H.隆德贝克有限公司 | 包括给予咪唑并吡嗪酮的组合治疗 |
TW201829394A (zh) * | 2016-12-21 | 2018-08-16 | 丹麥商H 朗德貝克公司 | 作為bace1抑制劑之6-胺基-5-氟-5-(氟甲基)-2,3,4,5-四氫吡啶-2-基-苯基-5-(甲氧基-d)-吡-2-甲醯胺及其氟化衍生物 |
SI3723807T1 (sl) | 2017-12-14 | 2022-01-31 | H. Lundbeck A/S | Kombinirana zdravljenja, ki obsegajo dajanje 1H-pirazolo(4,3-b)piridinov |
AR113926A1 (es) | 2017-12-14 | 2020-07-01 | H Lundbeck As | Derivados de 1h-pirazolo[4,3-b]piridinas |
CN117447475A (zh) | 2017-12-20 | 2024-01-26 | H.隆德贝克有限公司 | 作为PDE1抑制剂的吡唑并[4,3-b]吡啶和咪唑并[1,5-a]嘧啶 |
CN109970681A (zh) * | 2019-04-19 | 2019-07-05 | 安徽海康药业有限责任公司 | 一种瑞格列奈的合成方法 |
CN113720930A (zh) * | 2021-07-26 | 2021-11-30 | 南京一诺医药科技有限公司 | 一种hplc-ms/ms联用检测人血浆中奥美拉唑的方法 |
CN114235985A (zh) * | 2021-11-25 | 2022-03-25 | 南京海纳医药科技股份有限公司 | 一种hplc-ms/ms联用检测人血浆中胍法辛的方法 |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002100399A1 (en) | 2001-06-12 | 2002-12-19 | Elan Pharmaceuticals, Inc. | Macrocycles useful in the treatment of alzheimer's disease |
GB0124928D0 (en) | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
EP2258687B1 (en) | 2002-02-12 | 2012-12-26 | Glaxosmithkline LLC | Nicotinamide derivates useful as P38 inhibitors |
AR077277A1 (es) | 2009-07-09 | 2011-08-17 | Lilly Co Eli | Compuestos de biciclo (1,3)tiazin-2-amina formulacion farmaceutica que lo comprende y su uso para la manufactura de un medicamento util para el tratamiento de la enfermedad de alzheimer |
DK2580200T3 (en) | 2010-06-09 | 2017-01-09 | Janssen Pharmaceutica Nv | 5,6-dihydro-2H- [1,4] oxazin-3-YLAMINDERIVATER THAT COULD BE USED AS INHIBITORS OF BETA-secretase (BACE) |
CN103429589A (zh) | 2011-01-12 | 2013-12-04 | 诺瓦提斯公司 | 噁嗪衍生物及其在治疗神经障碍中的用途 |
PL2663561T3 (pl) | 2011-01-13 | 2016-10-31 | Nowe pochodne heterocykliczne i ich zastosowanie w leczeniu zaburzeń neurologicznych | |
US8754075B2 (en) | 2011-04-11 | 2014-06-17 | Hoffmann-La Roche Inc. | 1,3-oxazines as BACE1 and/or BACE2 inhibitors |
TW201247635A (en) | 2011-04-26 | 2012-12-01 | Shionogi & Co | Oxazine derivatives and a pharmaceutical composition for inhibiting BAC1 containing them |
BR112013031098A2 (pt) | 2011-06-07 | 2016-12-06 | Hoffmann La Roche | halogeno-alquil-1,3 oxazinas como inibidores de bace1 e/ou bace2 |
UY34278A (es) | 2011-08-25 | 2013-04-05 | Novartis Ag | Derivados novedosos de oxazina y su uso en el tratamiento de enfermedades |
US8338413B1 (en) | 2012-03-07 | 2012-12-25 | Novartis Ag | Oxazine derivatives and their use in the treatment of neurological disorders |
CA2867851A1 (en) | 2012-03-20 | 2013-09-26 | Elan Pharmaceuticals, Inc. | Spirocyclic dihydro-thiazine and dihydro-oxazine bace inhibitors, and compositions and uses thereof |
WO2014056816A1 (en) | 2012-10-10 | 2014-04-17 | F. Hoffmann-La Roche Ag | COMBINATION OF AN Aβ ANTIBODY AND A BACE INHIBITOR |
EP2912035A4 (en) | 2012-10-24 | 2016-06-15 | Shionogi & Co | DERIVATIVES OF DIHYDROOXAZINE OR OXAZEPINE HAVING BACE1 INHIBITING ACTIVITY |
AU2014223334C1 (en) | 2013-03-01 | 2018-10-18 | Amgen Inc. | Perfluorinated 5,6-dihydro-4H-1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use |
TWI639607B (zh) | 2013-06-18 | 2018-11-01 | 美國禮來大藥廠 | Bace抑制劑 |
EP3107897A1 (en) | 2014-02-19 | 2016-12-28 | H. Lundbeck A/S | 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease |
TW201623295A (zh) | 2014-04-11 | 2016-07-01 | 塩野義製藥股份有限公司 | 具有bace1抑制活性之二氫噻及二氫衍生物 |
MA40941A (fr) | 2014-11-10 | 2017-09-19 | H Lundbeck As | 2-amino-5,5-difluoro-6-(fluorométhyl)-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1 |
JO3458B1 (ar) | 2014-11-10 | 2020-07-05 | H Lundbeck As | 2- أمينو-6- (دايفلوروميثيل) – 5، 5- ديفلورو-6-فينيل-3،4، 5، 6-تيتراهيدروبيريدين كمثبطات bace1 |
CR20170187A (es) | 2014-11-10 | 2018-02-01 | H Lundbeck As | 2-Amino-3,5-difluoro-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas en calidad de inhibidores de BACE1 para el tratamiento de la enfermedad de Alzheimer |
TW201717948A (zh) | 2015-08-10 | 2017-06-01 | H 朗德貝克公司 | 包括給予2-胺基-3,5,5-三氟-3,4,5,6-四氫吡啶的聯合治療 |
MX2018001699A (es) | 2015-08-12 | 2018-05-07 | H Lundbeck As | 2-amino-3-fluoro-3-(fluorometil)-6-meti-6-fenil-3,4,5,6-tetrahidr opiridinas como inhibidores de bace1. |
-
2014
- 2014-11-09 CR CR20170187A patent/CR20170187A/es unknown
-
2015
- 2015-11-09 EA EA201790817A patent/EA201790817A1/ru unknown
- 2015-11-09 CN CN201580060814.7A patent/CN107074809A/zh active Pending
- 2015-11-09 RU RU2017116197A patent/RU2017116197A/ru unknown
- 2015-11-09 SG SG11201703177WA patent/SG11201703177WA/en unknown
- 2015-11-09 ES ES15790975T patent/ES2710602T3/es active Active
- 2015-11-09 MX MX2017006048A patent/MX2017006048A/es unknown
- 2015-11-09 EP EP15790975.5A patent/EP3218362B1/en active Active
- 2015-11-09 TN TN2017000134A patent/TN2017000134A1/en unknown
- 2015-11-09 AU AU2015345257A patent/AU2015345257A1/en not_active Abandoned
- 2015-11-09 CA CA2964305A patent/CA2964305A1/en not_active Abandoned
- 2015-11-09 US US15/524,479 patent/US10059669B2/en not_active Expired - Fee Related
- 2015-11-09 PE PE2017000827A patent/PE20170947A1/es unknown
- 2015-11-09 KR KR1020177012461A patent/KR20170082529A/ko unknown
- 2015-11-09 WO PCT/EP2015/076014 patent/WO2016075062A1/en active Application Filing
- 2015-11-09 JP JP2017525124A patent/JP2017533253A/ja active Pending
- 2015-11-09 BR BR112017009647A patent/BR112017009647A2/pt not_active Application Discontinuation
-
2017
- 2017-04-20 ZA ZA2017/02799A patent/ZA201702799B/en unknown
- 2017-05-03 IL IL252091A patent/IL252091A0/en unknown
- 2017-05-04 CL CL2017001113A patent/CL2017001113A1/es unknown
- 2017-05-04 PH PH12017500829A patent/PH12017500829A1/en unknown
- 2017-05-05 CO CONC2017/0004530A patent/CO2017004530A2/es unknown
- 2017-05-09 SV SV2017005434A patent/SV2017005434A/es unknown
- 2017-05-09 DO DO2017000118A patent/DOP2017000118A/es unknown
- 2017-05-09 EC ECIEPI201728463A patent/ECSP17028463A/es unknown
- 2017-05-10 NI NI201700056A patent/NI201700056A/es unknown
Also Published As
Publication number | Publication date |
---|---|
RU2017116197A (ru) | 2018-12-13 |
ES2710602T3 (es) | 2019-04-26 |
US10059669B2 (en) | 2018-08-28 |
BR112017009647A2 (pt) | 2017-12-19 |
CL2017001113A1 (es) | 2017-12-01 |
EP3218362B1 (en) | 2019-01-09 |
EP3218362A1 (en) | 2017-09-20 |
ECSP17028463A (es) | 2017-08-31 |
SG11201703177WA (en) | 2017-05-30 |
CA2964305A1 (en) | 2016-05-19 |
PH12017500829A1 (en) | 2017-10-09 |
AU2015345257A1 (en) | 2017-05-04 |
CN107074809A (zh) | 2017-08-18 |
KR20170082529A (ko) | 2017-07-14 |
DOP2017000118A (es) | 2017-07-15 |
JP2017533253A (ja) | 2017-11-09 |
SV2017005434A (es) | 2017-07-19 |
WO2016075062A1 (en) | 2016-05-19 |
ZA201702799B (en) | 2018-08-29 |
CO2017004530A2 (es) | 2017-07-28 |
CR20170187A (es) | 2018-02-01 |
TN2017000134A1 (en) | 2018-10-19 |
IL252091A0 (en) | 2017-07-31 |
MX2017006048A (es) | 2017-06-19 |
NI201700056A (es) | 2017-09-22 |
US20170313658A1 (en) | 2017-11-02 |
PE20170947A1 (es) | 2017-07-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201790817A1 (ru) | 2-амино-3,5-дифтор-3,6-диметил-6-фенил-3,4,5,6-тетрагидропиридины как ингибиторы bace1 для лечения болезни альцгеймера | |
PH12016501600A1 (en) | 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease | |
EA201790818A1 (ru) | 2-амино-6-(дифторметил)-5,5-дифтор-6-фенил-3,4,5,6-тетрагидропиридины как ингибиторы bace1 | |
EA201791030A1 (ru) | 2-амино-5,5-дифтор-6-(фторметил)-6-фенил-3,4,5,6-тетрагидпропиридины в качестве ингибиторов bace1 | |
EA201891203A1 (ru) | Гетероциклические соединения в качестве иммуномодуляторов | |
EA202091709A1 (ru) | Ингибиторы днк-пк | |
EA201790764A1 (ru) | Новые соединения карбоновых кислот, подходящие для ингибирования микросомальной простагландин-e2-синтазы 1 | |
EA201590353A1 (ru) | Способы лечения болезни альцгеймера и фармацевтические композиции | |
EA201791259A1 (ru) | Производные пиперидина в качестве ингибиторов hdac1/2 | |
EA201890449A1 (ru) | Фумагиллиновые гетероциклические соединения и способы их получения и применения | |
EA201790206A1 (ru) | Новые 2,5-замещенные пиримидины в качестве ингибиторов pde4 | |
EA201790207A1 (ru) | Новые замещенные пиримидиновые соединения | |
MX2018012902A (es) | Composiciones y métodos para el tratamiento de trastornos de almacenamiento lisosomal y trastornos caracterizados por disfunción lisosomal. | |
EA202091708A1 (ru) | Ингибиторы днк-пк | |
EA201791367A1 (ru) | Соединения 2,3,4,5-тетрагидропиридин-6-амин и 3,4-дигидро-2h-пиррол-5-амин - ингибиторы бета-секретазы | |
EA202090414A1 (ru) | Соединения и их применение | |
EA201790830A1 (ru) | Ингибиторы альдостеронсинтазы | |
EA201790253A1 (ru) | Ингибиторы альдостеронсинтазы | |
EA201790209A1 (ru) | Новые 2,5-замещенные пиримидины в качестве ингибиторов pde | |
EA201790315A1 (ru) | Модуляторы x-рецепторов печени | |
EA201590884A1 (ru) | Способы лечения заболеваний печени | |
EA201890460A1 (ru) | Композиции и способы лечения и предотвращения нейродегенеративных расстройств | |
PH12017501668A1 (en) | Bace1 inhibitors | |
MX2016008968A (es) | Compuestos organicos. |